Abstract
Dental diseases are perhaps the most prevalent infection-related diseases in humans. Biofilm is involved in almost every infectious disease compromising oral health, notably caries, periodontal disease, gingivitis, endodontic infections and peri-implantitis. Current therapies of biofilm-derived oral infections lack sensitivity; they are not species-specific and kill pathogenic species as well as commensal species, which are protective against the formation of pathogenic biofilms. Moreover, antibiotics have a limited effect on biofilm and are almost unused in oral diseases.
A promising alternative approach is bacteriophage (phage) therapy. Phages play a key role in the natural balance in a predator-prey relationship with bacteria and thus have the potential to be efficient anti-bacterial agents. Phages are highly efficient against biofilm, strain specific and easy to isolate and manipulate. Thus, like in many other medicinal fields, phage therapy offers new horizons to dentistry, both therapeutics and research. The present review presents the etiology of common oral diseases, characterization of the infection and the treatment challenges of phage therapy in dentistry. Recent findings and development in the use of phages for prevention, control, and treatment of oral infections as well as possibilities of engineering the oral microbiome are discussed.Keywords: Bacteriophage, Phage, Biofilm, Caries, Dentistry, Oral, Periodontal disease, Phage therapy, Antibiotic resistance, Multi drug resistant bacteria.
Current Topics in Medicinal Chemistry
Title:Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens
Volume: 17 Issue: 10
Author(s): Mor Shlezinger, Leron Khalifa, Yael Houri-Haddad, Shunit Coppenhagen-Glazer, Grégory Resch, Yok-Ai Que, Shaul Beyth, Elisheva Dorfman, Ronen Hazan and Nurit Beyth
Affiliation:
Keywords: Bacteriophage, Phage, Biofilm, Caries, Dentistry, Oral, Periodontal disease, Phage therapy, Antibiotic resistance, Multi drug resistant bacteria.
Abstract: Dental diseases are perhaps the most prevalent infection-related diseases in humans. Biofilm is involved in almost every infectious disease compromising oral health, notably caries, periodontal disease, gingivitis, endodontic infections and peri-implantitis. Current therapies of biofilm-derived oral infections lack sensitivity; they are not species-specific and kill pathogenic species as well as commensal species, which are protective against the formation of pathogenic biofilms. Moreover, antibiotics have a limited effect on biofilm and are almost unused in oral diseases.
A promising alternative approach is bacteriophage (phage) therapy. Phages play a key role in the natural balance in a predator-prey relationship with bacteria and thus have the potential to be efficient anti-bacterial agents. Phages are highly efficient against biofilm, strain specific and easy to isolate and manipulate. Thus, like in many other medicinal fields, phage therapy offers new horizons to dentistry, both therapeutics and research. The present review presents the etiology of common oral diseases, characterization of the infection and the treatment challenges of phage therapy in dentistry. Recent findings and development in the use of phages for prevention, control, and treatment of oral infections as well as possibilities of engineering the oral microbiome are discussed.Export Options
About this article
Cite this article as:
Shlezinger Mor, Khalifa Leron, Houri-Haddad Yael, Coppenhagen-Glazer Shunit, Resch Grégory, Que Yok-Ai, Beyth Shaul, Dorfman Elisheva, Hazan Ronen and Beyth Nurit, Phage Therapy: A New Horizon in the Antibacterial Treatment of Oral Pathogens, Current Topics in Medicinal Chemistry 2017; 17 (10) . https://dx.doi.org/10.2174/1568026616666160930145649
DOI https://dx.doi.org/10.2174/1568026616666160930145649 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology LC-MS for Simultaneous Determination of Vancomycin and Teicoplanin in Patient Plasma and its Application to Therapeutic Drug Monitoring
Current Pharmaceutical Analysis Protective Effects of Astaxanthin on Nephrotoxicity in Rats with Induced Renovascular Occlusion
Combinatorial Chemistry & High Throughput Screening Long-term Results After Transcatheter Aortic Valve Implantation: What do we Know Today?
Current Cardiology Reviews Epidemiology of Septic Acute Kidney Injury
Current Drug Targets Current and Future Approaches to the Prevention and Treatment of Staphylococcal Medical Device-Related Infections
Current Pharmaceutical Design Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Nano-zinc Coordination with the Ligands of Carboplatin, Oxaliplatin and Nedaplatin. Synthesis, Characterization and Biological Properties
Letters in Organic Chemistry Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Dendrimers and Dendritic Polymers as Anti-infective Agents: New Antimicrobial Strategies for Therapeutic Drugs
Anti-Infective Agents in Medicinal Chemistry Clopidogrel and Aspirin in Cardiovascular Medicine: Responders or Not -- Current Best Available Evidence
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Chromogranin A-Derived Peptides Are Involved in Innate Immunity
Current Medicinal Chemistry Amphotericin B LIPOMER for Enhanced Splenic Delivery
Drug Delivery Letters Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Current Evidence on the Evaluation and Management of Fever Without a Source in Infants Aged 0-90 Days: A Review
Reviews on Recent Clinical Trials Susceptibility of Periodontopathogenic and Cariogenic Bacteria to Defensins and Potential Therapeutic Use of Defensins in Oral Diseases
Current Pharmaceutical Design